论文部分内容阅读
目的观察奥沙拉嗪对溃疡性结肠炎(UC)患者血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和白细胞介素-8(IL-8)的影响。方法将70例UC患者随机分成对照组和治疗组,每组35例。对照组患者予柳氮磺吡啶治疗,治疗组患者予奥沙拉嗪治疗,疗程均为8周。观察治疗前后临床症状、结肠镜下黏膜改变以及血清TNF-α、IL-6和IL-8水平的变化。结果治疗组患者临床疗效与对照组比较,差异无统计学意义(P>0.05);两组患者血清TNF-α、IL-6和IL-8水平均较治疗前显著降低(P<0.01),但治疗组下降更明显。结论奥沙拉嗪治疗UC疗效显著,并可降低患者血清TNF-α、IL-6和IL-8水平,抑制炎症反应,可能是其治疗UC的机制之一。
Objective To investigate the effect of olsalazine on serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8) in patients with ulcerative colitis. Methods Seventy patients with UC were randomly divided into control group and treatment group, 35 cases in each group. Patients in the control group were treated with sulfasalazine, and patients in the treatment group were treated with olsalazine for 8 weeks. Clinical symptoms before and after treatment, colon mucosal changes and changes of serum TNF-α, IL-6 and IL-8 levels were observed. Results There was no significant difference in clinical efficacy between the two groups (P> 0.05). The levels of TNF-α, IL-6 and IL-8 in the two groups were significantly lower than those before treatment (P <0.01) But the treatment group decreased more obviously. Conclusion Ozrazine treatment of UC significant effect, and can reduce serum TNF-α, IL-6 and IL-8 levels, inhibit the inflammatory response may be one of the mechanisms of its treatment of UC.